MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VENTER, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VENTER, J. C.

Molecular Pharmacology, Vol 16, 429-440, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics

High Efficiency Coupling Between Beta-adrenergic Receptors and Cardiac Contractility: Direct Evidence for "Spare" Beta-adrenergic Receptors

J. CRAIG VENTER 1

1 Department of Pharmacology and Therapeutics, School of Medicine, State University of New York at Buffalo, 127 Farber Hall, Buffalo, New York 14214

The relationship between the concentration of beta-adrenergic receptors and the activation of heart muscle by isoproterenol was investigated using the irreversible beta-adrenergic receptor antagonist NHNP-NBE. The interaction of NHNP-NBE with beta-receptors was characterized in isolated membranes, whole cells and intact cardiac muscle, using [125I]-iodohydroxybenzylpindolol (IHYP). Formation of the NHNP-NBE-beta-receptor complex was found to be irreversible and dependent on incubation time, temperature and ligand concentration. Occupation of beta-receptors by adrenergic ligands prior to NHNP-NBE exposure protected the receptors from inactivation. These data are consistent with a covalent modification of beta-receptors by NHNP-NBE at a site in or near the adrenergic ligand binding site. Incubation of NHNP-NBE with intact cardiac muscle produced a dose dependent beta-receptor inactivation that survived tissue homogenization and membrane isolation. NHNP-NBE dramatically affects the concentrations at which isoproterenol produces positive inotropic responses in cat papillary muscles. The ED50 for isoproterenol under control conditions averaged 9.8 nM. The ED50 of isoproterenol increased to 22; 70; 500 and 5623 nM subsequent to a 10 min treatment of the muscles with 0.1; 1.0; 10 and 100 µM NHNP-NBE respectively. The same maximum inotropic response was achieved with isoproterenol following each concentration of NHNP-NBE. Ten micromolar isoproterenol subsequent to 100 µM NHNP-NBE increased the papillary muscle concentration of cyclic AMP to the same extent as 10 µM isoproterenol alone. Although the maximum cyclic AMP response was essentially identical, the time course for cyclic AMP production was substantially slower following irreversible beta-receptor blockade. The ED50 for isoproterenol induced increases in cyclic AMP concentrations was 15 nM in the absence of NHNP-NBE and 600 nM following 100 µM NHNP-NBE. In contrast to the cardiac data, NHNP-NBE stoichiometrically inhibited IHYP binding and isoproterenol induced cyclic AMP formation in cultured human lung (VA2) cells. These data indicate a high efficiency coupling between the isoproterenol-beta-adrenergic receptor interaction, cyclic AMP formation and increased cardiac contractility, an efficiency not apparent with isoproterenol-induced cyclic AMP formation in cultured cells.

Note:
ACKNOWLEDGMENT The author is indebted to Ms. Rose Agro for excellent technical assistance and Dr. David Triggle for the synthesis of NHNP-NBE.

Submitted on October 23, 1978
Accepted on May 14, 1979







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics